Melanoma Staging and Prognosis: TNM Classification, Breslow Depth, and Survival Outcomes

Clinical Overview

Accurate staging of melanoma is essential for prognostic counseling, treatment decision-making, and surveillance planning. The tumor, node, metastasis (TNM) classification system, updated to the 8th edition in 2017 by the American Joint Committee on Cancer (AJCC), provides a standardized framework for staging cutaneous melanoma based on histopathologic and clinical findings. TNM staging integrates Breslow depth (vertical thickness in millimeters), Clark level (invasion depth into dermal layers), mitotic rate, ulceration status, sentinel lymph node (SLN) biopsy results, and presence of distant metastases. This staging system allows reliable stratification of patients into prognostic groups, guides adjuvant therapy decisions, and enables comparison of outcomes across institutions and clinical trials.

Epidemiology & Risk Factors

Melanoma incidence has increased approximately 3% annually in the United States over the past two decades, though this increase is primarily in early-stage disease attributable to improved detection and screening awareness. The distribution of melanoma by stage at diagnosis varies geographically and by healthcare access: in developed countries with robust dermatology services, approximately 85-90% of melanomas are Stage I-II (localized disease), while developing countries and underserved populations present with higher proportion of advanced-stage disease (Stage III-IV). Factors influencing stage at presentation include: patient awareness and skin self-examination practices, access to dermatology care, provider education regarding melanoma recognition, and presence of risk factors (prior melanoma history). Patients with prior personal history of melanoma have 5-10% risk of developing subsequent primary melanoma, necessitating intensive surveillance.

Pathophysiology

TNM staging reflects the pathophysiology of melanoma progression from localized to regional to distant disease. Breslow depth serves as the most important prognostic factor because it correlates with the probability of occult lymph node and distant metastases. Thin melanomas (≤1mm) have <5% risk of SLN positivity, while thick melanomas (>4mm) have 25-40% risk. Clark level indicates the anatomic invasion into dermal layers: Level I (in situ, confined to epidermis) has virtually zero metastatic risk, while Level IV (invasion into reticular dermis) carries significant nodal metastasis risk. Mitotic rate reflects melanoma cell proliferation activity: ≥1 mitosis per mm² indicates aggressive biology and increases stage within each Breslow depth category. Ulceration represents tumor necrosis breaking through the overlying epidermis and indicates more aggressive phenotype, reducing survival by approximately 10% within each stage group. SLN positivity indicates regional metastatic disease (Stage III) and is the single most important prognostic factor beyond the primary tumor, reducing 5-year survival by 25-40% depending on tumor burden and number of involved nodes.

Clinical Presentation & Classification

TNM Stage Ia: Localized Melanoma

Stage IA melanoma (Breslow ≤0.8mm, Clark level I-II, no ulceration, mitotic rate <1/mm²) has excellent prognosis with 5-year melanoma-specific survival >95% and 10-year survival approaching 90%. These thin melanomas have minimal risk of metastasis; SLN biopsy is not routinely performed. Treatment is wide local excision alone.

TNM Stage Ib: Localized Melanoma

Stage IB encompasses: (1) Breslow 0.81-1.0mm without ulceration (any Clark/mitotic rate), or (2) Breslow ≤1.0mm with ulceration. Five-year survival is 90-95%. SLN biopsy may be considered for patient and physician preference; some guidelines recommend discussion of risks/benefits rather than routine recommendation.

TNM Stage IIa: Intermediate Melanoma

Stage IIA: Breslow 1.01-2.0mm without ulceration. Five-year survival is 80-85%. SLN biopsy is recommended due to approximately 15-20% risk of nodal positivity.

TNM Stage IIb: Intermediate Melanoma

Stage IIB encompasses: (1) Breslow 2.01-4.0mm without ulceration, or (2) Breslow 1.01-2.0mm with ulceration. Five-year survival is 65-75%. SLN biopsy is strongly recommended; approximately 20-30% of patients are SLN-positive.

TNM Stage IIc: High-Risk Localized Melanoma

Stage IIC: Breslow >4.0mm with or without ulceration. Five-year survival is 40-50% without adjuvant therapy, improving to 55-65% with adjuvant immunotherapy. SLN biopsy is strongly recommended; approximately 40-50% of Stage IIC patients are SLN-positive.

TNM Stage III: Regional Metastatic Melanoma

Stage IIIA: Clinically occult SLN metastases (discovered only on SLN biopsy) detected in 1-3 nodes with microscopic disease. Five-year survival is 60-75%. IIIB: macroscopic regional nodal disease involving 1-3 nodes, or any number of nodes with in-transit/satellite metastases. Five-year survival is 40-50%. IIIC: macroscopic disease in ≥4 nodes or any nodal disease with in-transit/satellite metastases. Five-year survival is 20-30%. Adjuvant immunotherapy (ipilimumab or pembrolizumab) improves recurrence-free survival by 20-30%.

TNM Stage IV: Distant Metastatic Melanoma

Stage IV melanoma indicates distant metastases: IVA (skin, subcutaneous, or lymph node metastases), IVB (lung metastases without other organ involvement), IVC (other visceral metastases or elevated LDH). Median overall survival is 8-12 months with single-agent immunotherapy, improving to 18-24 months with combination immunotherapy or targeted therapy.

Diagnosis & Staging

Accurate histopathologic assessment is essential for TNM staging. Breslow depth is measured from the granular layer of the epidermis to the deepest point of melanoma invasion, using an ocular micrometer on the microscope. Clark level is assessed: I (in situ), II (invasion into papillary dermis), III (filling papillary dermis), IV (invasion into reticular dermis), V (invasion into subcutaneous fat). Mitotic rate is counted as number of mitoses per 1.0 mm² in the most mitotically active area of the tumor, expressed as mitoses/mm². Ulceration is presence of epidermal discontinuity overlying the tumor (not secondary ulceration from trauma). Tumor infiltrating lymphocyte (TIL) response is assessed (absent, non-brisk, brisk) and is prognostically relevant but not incorporated into TNM stage. Margins of the specimen are examined for tumor involvement. Sentinel lymph node biopsy is indicated for Breslow 0.8-4.0mm to determine if SLN is involved, which changes staging from Stage I-II to Stage IIIA-IIIC. SLN biopsy involves: (1) lymphoscintigraphy with radioactive tracer to identify draining basin(s), (2) intraoperative mapping and blue dye injection, (3) removal of identified SLN(s), and (4) detailed pathologic examination including routine histology, immunohistochemistry, and serial sectioning to detect micrometastases. SLN positivity is approximately: 5% for Breslow 0.8-1.0mm, 15-20% for Breslow 1.01-2.0mm, 30-40% for Breslow 2.01-4.0mm, and 40-50% for Breslow >4.0mm.

Treatment Algorithm

Treatment depends on TNM stage: Stage IA-IB localized melanoma is treated with wide local excision alone (0.5-1.0cm margins for ≤1mm, 1.0cm margins for 1.01-2.0mm). Stage IIA-IIC localized melanoma is treated with wide local excision and SLN biopsy; if SLN is negative, observation is routine practice, though adjuvant therapy may be discussed. If SLN is positive (Stage IIIA-IIIC), completion lymph node dissection is performed, and adjuvant immunotherapy is strongly recommended: ipilimumab 3mg/kg IV every 3 weeks for 4 doses induction, then 3mg/kg every 12 weeks for maintenance (maximum 2 years) improves recurrence-free survival from 50% to 70% at 3 years (EORTC 18071, CheckMate 069). Alternatively, pembrolizumab 200mg IV every 3 weeks for up to 1 year similarly improves RFS (KEYNOTE-054). For BRAF-mutant Stage III disease, dabrafenib 100mg twice daily plus trametinib 2mg daily improves RFS compared to observation. For distant metastatic disease (Stage IV), systemic therapy is indicated: pembrolizumab 2mg/kg IV every 3 weeks or nivolumab 3mg/kg IV every 2 weeks (median response rate 40-50%, median PFS 11-12 months with monotherapy). Combination nivolumab 1mg/kg plus ipilimumab 3mg/kg every 3 weeks for 4 doses followed by nivolumab maintenance achieves response rates of 60% and median OS >60 months in responders (CheckMate 067). For BRAF V600E-mutant metastatic disease, dabrafenib 100mg twice daily plus trametinib 2mg daily achieves response rates of 64-70% (COMBI-d trial). For KIT-mutant melanoma, imatinib 400-600mg daily, sunitinib, or nilotinib are options.

Prognosis & Survival

Survival depends primarily on TNM stage at diagnosis:

  • Stage IA (≤0.8mm, no ulceration): 5-year survival 95%, 10-year survival 90%
  • Stage IB (0.81-1.0mm or ≤1.0mm with ulceration): 5-year survival 90-95%, 10-year survival 87-90%
  • Stage IIA (1.01-2.0mm, no ulceration): 5-year survival 80-85%, 10-year survival 75-80%
  • Stage IIB (2.01-4.0mm, no ulceration or 1.01-2.0mm with ulceration): 5-year survival 65-75%, 10-year survival 60-70%
  • Stage IIC (>4.0mm, any ulceration status): 5-year survival 40-50%, 10-year survival 35-45%
  • Stage IIIA (occult SLN micrometastases): 5-year survival 60-75%, 10-year survival 50-65%
  • Stage IIIB (1-3 macroscopic nodes): 5-year survival 40-50%, 10-year survival 30-40%
  • Stage IIIC (≥4 nodes or in-transit metastases): 5-year survival 20-30%, 10-year survival 10-20%
  • Stage IV (distant metastases): Median survival 8-12 months without treatment, 18-24 months with immunotherapy, up to 60 months in responding patients with combination therapy

Adjuvant immunotherapy improves recurrence-free survival by 25-30% for Stage IIIA-IIIC disease. Presence of ulceration reduces survival by approximately 10% within each stage. High mitotic rate (≥1/mm²) reduces survival by approximately 5-10%. Multiple involved lymph nodes reduce survival substantially: IIIA with 1 positive node has better outcome than IIIB with 1-3 macroscopic nodes, which in turn has better outcome than IIIC with ≥4 nodes.

When to See a Dermatologist

Patients with newly diagnosed melanoma require dermatology and oncology consultation for staging assessment and treatment planning. After initial treatment, surveillance intervals depend on stage: Stage I patients require annual dermatology examination with skin self-examination monthly. Stage II patients require examination every 3-6 months. Stage III patients require examination every 3 months for the first 2 years, then every 3-6 months. Stage IV patients typically have baseline imaging (CT chest/abdomen/pelvis, brain MRI if clinically indicated) and regular oncology follow-up every 4-12 weeks depending on treatment.

Frequently Asked Questions

My melanoma is 1.5mm Breslow depth. What stage is it, and what's my prognosis?

A melanoma with 1.5mm Breslow depth is Stage IIA (assuming no ulceration and no SLN involvement). Five-year survival for Stage IIA is 80-85%. You should have SLN biopsy to determine if lymph nodes are involved; if SLN is negative, prognosis is excellent with 85-90% 10-year survival. If SLN is positive, staging changes to IIIA-IIIC depending on nodal burden, and adjuvant immunotherapy is recommended to improve recurrence-free survival.

What does it mean if my sentinel lymph node biopsy is positive?

SLN positivity indicates regional metastatic disease—melanoma cells have spread to lymph nodes, changing your stage from localized (I-II) to regional (Stage III). This substantially changes treatment and prognosis. You will typically have completion lymph node dissection (removal of all lymph nodes in the involved basin) and should receive adjuvant immunotherapy for 1-2 years. With adjuvant therapy, recurrence-free survival improves significantly. Regular surveillance is essential to detect any future recurrence.

I have Stage IIIB melanoma with 2 positive lymph nodes. Will adjuvant therapy improve my outcome?

Yes. Stage IIIB with limited nodal involvement (1-3 nodes) has 5-year survival of 40-50% with observation alone. Adjuvant immunotherapy with pembrolizumab or ipilimumab improves recurrence-free survival by 25-30%, resulting in approximately 65-70% 2-year recurrence-free survival. Treatment for 1 year (pembrolizumab) or 2 years (ipilimumab maintenance) is standard. Discuss side effects and benefits with your oncologist to determine which option is best for you.

My Breslow depth is 4.2mm (Stage IIC). Is my prognosis hopeless?

No. Stage IIC melanoma has 5-year survival of 40-50% without adjuvant therapy, which is sobering, but it is not hopeless. With complete surgical excision and adjuvant immunotherapy, outcomes improve substantially. Additionally, if you develop recurrence, modern immunotherapy and targeted therapy options offer meaningful survival benefit. Regular surveillance allows earlier detection of any recurrence. Your individual prognosis depends on many factors including SLN status, presence of ulceration, and response to adjuvant therapy.

References

  1. Gershenwald JE, Scolyer M, Khatri R, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472-492.
  2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19(16):3622-3634.
  3. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
  4. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus Merck's anti-PD-L1 Keytruda (pembrolizumab) versus placebo plus Keytruda in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2022;400(10368):1682-1696.
  5. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo in resected Stage III IIM melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522-530.
  6. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823.
  7. Sladden MJ, Balch C, Barzilai DA, et al. Surgical excision margins for primary cutaneous melanoma. J Am Acad Dermatol. 2012;66(3):395-404.
  8. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
  9. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Khattak A. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(5):v126-v132.
  10. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer staging system. J Clin Oncol. 2001;19(16):3622-3634.

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.